• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Healthcare·SHG.AX
Share

Singular Health Group Ltd Stocks

A$ 0.18Last Updated 01.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

A$ 41.01M

A$ 0.18
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Singular Health Group Ltd operates as a medical technology enterprise dedicated to developing and commercializing a volumetric rendering platform (VRP). This advanced platform facilitates the three-dimensional and virtual reality presentation of anatomy, drawing upon standard radiological imaging. Among its key offerings are the 3Dicom Viewer, a cross-compatible software application designed for users to engage with conventional 2D medical images; 3DicomVSP, a complete system for surgical planning; Health Academy, a adaptable, multi-language platform delivering structured, curriculum-aligned educational modules; and GeoVR, a cloud-based solution specifically engineered for the mineral resources industry. The company, founded in 2017, is headquartered in Subiaco, Australia.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.10.2026 18:41

A Test of Resilience: What Nubank and Revolut Will Face in the U.S. Market

01.10.2026 18:08

A Classic Makes a Comeback: The 60/40 Portfolio Could Be Effective for the First Time Since 2021

01.10.2026 17:30

Shares of biotech company Capricor had their best day in a month. What inspired investors?

01.10.2026 16:53

From Coke to IMAX: 10 Companies Bloomberg Recommends Watching in the Fourth Quarter

01.10.2026 15:45

Morning in New York: Indices Seek Equilibrium

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026